TELA Bio, Inc. (TELA)
NASDAQ: TELA · IEX Real-Time Price · USD
4.630
0.00 (0.00%)
May 2, 2024, 4:00 PM EDT - Market closed
TELA Bio Revenue
In the year 2023, TELA Bio had annual revenue of $58.45M with 41.13% growth. Revenue in the quarter ending December 31, 2023 was $17.00M with 46.26% year-over-year growth.
Revenue (ttm)
$58.45M
Revenue Growth
+41.13%
P/S Ratio
1.95
Revenue / Employee
$257,502
Employees
227
Market Cap
114.15M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 58.45M | 17.04M | 41.13% |
Dec 31, 2022 | 41.42M | 11.96M | 40.58% |
Dec 31, 2021 | 29.46M | 11.25M | 61.77% |
Dec 31, 2020 | 18.21M | 2.77M | 17.91% |
Dec 31, 2019 | 15.45M | 7.17M | 86.68% |
Dec 31, 2018 | 8.27M | 4.03M | 94.91% |
Dec 31, 2017 | 4.25M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
TruBridge | 339.44M |
FibroGen | 147.75M |
CytomX Therapeutics | 101.21M |
Abeona Therapeutics | 3.50M |
GlycoMimetics | 10.00K |
TELA News
- 7 days ago - TELA Bio to Announce First Quarter 2024 Financial Results - GlobeNewsWire
- 17 days ago - TELA Bio Announces U.S. Commercial Launch of Robotic-Compatible OviTex® IHR – Addressing the Need for a More Natural Repair in Inguinal Hernia Procedures - GlobeNewsWire
- 24 days ago - TELA Bio Welcomes Acclaimed Surgeon as Vice President of Medical Affairs and Surgeon Strategy - GlobeNewsWire
- 6 weeks ago - TELA Bio Achieves Record Fourth Quarter and Full Year 2023 Revenues and Reports Complete Financial Results - GlobeNewsWire
- 6 weeks ago - TELA Bio Announces U.S. Commercial Launch of LIQUIFIX™ – the Only FDA-Approved Liquid Adhesive for Internal Use in Hernia Surgery - GlobeNewsWire
- 6 weeks ago - TELA Bio Announces Sale of Distribution Rights for Wound Care Product to MIMEDX - GlobeNewsWire
- 2 months ago - TELA Bio to Announce Fourth Quarter and Full Year 2023 Financial Results - GlobeNewsWire
- 2 months ago - TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire